Biocryst Pharmaceuticals Inc.
BCRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.38B
Close$
$7.62
22.4% downside
Current Fair Value
22.4% downsideOvervalued by 22.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.38 Billion |
|---|---|
| Enterprise Value | $2.65 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.26 |
| Beta | 0.54 |
| Outstanding Shares | 254,481,000 |
Return
| Return on Equity | 84.68% |
|---|---|
| Return on Assets | -68.96% |
| Return on Invested Capital | -88.67% |
Valuation & Multiples
| P/E Ratio | -6.52 |
|---|---|
| PEG | -0.45 |
| Price to Sales | 3.27 |
| Price to Book Ratio | -4.91 |
| Enterprise Value to Revenue | 2.82 |
| Enterprise Value to EBIT | -8.57 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
$183.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$165.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5953▲ 14.31% |
|---|---|
| Total Calls | 161,600▼ 86.53% |
| Total Puts | 96,200▼ 82.26% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.15%▼ 77.65% |
|---|---|
| Total Invested | $608.54M▼ 74.33% |
| Investors Holding | 121▼ 194.00% |
ESG Score
No data
About Biocryst Pharmaceuticals Inc.
CEO: Jon Stonehouse